India – Intas to provide 2 million hydroxychloroquine tablets for WHO study on COVID-19

Intas Pharmaceuticals Ltd. has said it will provide up to two million tablets of hydroxychloroquine to World Health Organisation-endorsed study into the prevention of COVID-19 infection using hydroxychloroquine, free of charge, along with two million tablets of matched placebo.

Intas informed that it is collaborating on the WHO-endorsed study using hydroxychloroquine, a drug that may have an effect in preventing and/or reducing symptoms of COVID-19. The global COPCOV (chloroquine / hydroxychloroquine prevention of COVID-19 in the healthcare setting; a randomised, placebo-controlled prophylaxis) study involves 40,000 frontline healthcare workers who are caring for COVID-19 patients and is due to start shortly…